High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanoma

American Journal of Clinical Pathology

Volumn 142, Issue 1, 2014, Pages 121-132

  Alvino, Ester ^a   Passarelli, Francesca ^b   Cannavò, Elda ^c   Fortes, Cristina ^b   Mastroeni, Simona ^b   Caporali, Simona ^b   Jiricny, Josef ^c   Cappellini, Gian Carlo Antonini ^b   Scoppola, Alessandro ^b   Marchetti, Paolo ^d   Modesti, Andrea ^e   D'Atri, Stefania ^b  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Melanoma; Mismatch repair; MSH6; Survival

Indexed keywords

MESSENGER RNA; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH6;

ADULT; AGE; AGED; ARM; ARTICLE; BRESLOW THICKNESS; CANCER CELL; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; CONCENTRATION (PARAMETERS); DISEASE SEVERITY; EVALUATION STUDY; FEMALE; GENDER; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEG; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN ULCER; TRUNK;

MELANOMA; MISMATCH REPAIR; MSH6; SURVIVAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; ADULT; AGED; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEVUS; NUCLEAR PROTEINS; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84904545812     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPCX2D9YULBBLG     Document Type: Article

References (46)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol. 2009;27:6199-6206.
4. Davar D, Tarhini AA, Kirkwood JM. Adjuvant therapy for melanoma. Cancer J. 2012;18:192-202.
5. Tarhini AA, Gogas H, Kirkwood JM. IFN-alpha in the treatment of melanoma. J Immunol. 2012;189:3789-3793.
6. Timar J, Gyorffy B, Raso E. Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis. 2010;27:371-387.
7. Schramm SJ, Campain AE, Scolyer RA, et al. Review and cross-validation of gene expression signatures and melanoma prognosis. J Invest Dermatol. 2012;132:274-283.
8. Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006;98:472-482.
9. Alonso SR, Tracey L, Ortiz P, et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 2007;67:3450-3460. (Pubitemid 46724886)
10. Kauffmann A, Rosselli F, Lazar V, et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene. 2008;27:565-573. (Pubitemid 351158908)
11. Conway C, Mitra A, Jewell R, et al. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res. 2009;15:6939-6946.
12. Jewell R, Conway C, Mitra A, et al. Patterns of expression of DNA repair genes and relapse from melanoma. Clin Cancer Res. 2010;16:5211-5221.
13. Harbst K, Staaf J, Lauss M, et al. Molecular profiling reveals low- and high-grade forms of primary melanoma. Clin Cancer Res. 2012;18:4026-4036.
14. Brunner G, Reitz M, Heinecke A, et al. A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol. 2013;139:249-258.
15. Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008;18:85-98.
16. Pena-Diaz J, Jiricny J. Mammalian mismatch repair: error-free or error-prone? Trends Biochem Sci. 2012;37:206-214.
17. Barnhill RL. Pathology of Melanocytic Nevi and Malignant Melanoma. Boston, MA: Butterworth-Heinemann; 1995.
18. Alvino E, Marra G, Pagani E, et al. High-frequency microsatellite instability is associated with defective DNA mismatch repair in human melanoma. J Invest Dermatol. 2002;118:79-86. (Pubitemid 34107427)
19. Hussein MR, Roggero E, Sudilovsky EC, et al. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas. Am J Dermatopathol. 2001;23:308-314. (Pubitemid 32729440)
20. Shpitz B, Klein E, Malinger P, et al. Altered expression of the DNA mismatch repair proteins hMLH1 and hMSH2 in cutaneous dysplastic nevi and malignant melanoma. Int J Biol Markers. 2005;20:65-68. (Pubitemid 40667602)
21. Moraes MC, Neto JB, Menck CF. DNA repair mechanisms protect our genome from carcinogenesis. Front Biosci. 2012;17:1362-1388.
22. Sarasin A, Kauffmann A. Overexpression of DNA repair genes is associated with metastasis: a new hypothesis. Mutat Res. 2008;659:49-55.
23. Korabiowska M, Dengler H, Kellner S, et al. Decreased expression of MLH1, MSH2, PMS1 and PMS2 in pigmented lesions indicates accumulation of failed DNA repair along with malignant transformation and tumour progression. Oncol Rep. 1997;4:653-655. (Pubitemid 27210217)
24. Rass K, Gutwein P, Welter C, et al. DNA mismatch repair enzyme hMSH2 in malignant melanoma: increased immunoreactivity as compared to acquired melanocytic nevi and strong mRNA expression in melanoma cell lines. Histochem J. 2001;33:459-467. (Pubitemid 34229663)
25. Alonso SR, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol. 2004;164:193-203. (Pubitemid 38364604)
26. Song L, Robson T, Doig T, et al. DNA repair and replication proteins as prognostic markers in melanoma. Histopathology. 2013;62:343-350.
27. Smolle J, Soyer HP, Kerl H. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody: a quantitative immunohistochemical study. Am J Dermatopathol. 1989;11:301-307. (Pubitemid 19185400)
28. Li LX, Crotty KA, McCarthy SW, et al. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2000;22:489-495. (Pubitemid 32054841)
29. Florell SR, Boucher KM, Holden JA, et al. Failure to detect differences in proliferation status of nevi from CDKN2A mutation carriers and non-carriers. J Invest Dermatol. 2002;118:386-387. (Pubitemid 34158498)
30. Florell SR, Bowen AR, Hanks AN, et al. Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J Cutan Pathol. 2005;32:45-49. (Pubitemid 40174105)
31. Husain EA, Mein C, Pozo L, et al. Heterogeneous topographic profiles of kinetic and cell cycle regulator microsatellites in atypical (dysplastic) melanocytic nevi. Mod Pathol. 2011;24:471-486.
32. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;30:117-122. (Pubitemid 351441982)
33. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048-8056. (Pubitemid 46657407)
34. Meyer S, Fuchs TJ, Bosserhoff AK, et al. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One. 2012;7:e38222.
35. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101:452-474.
36. Moore DA, Pringle JH, Saldanha GS. Prognostic tissue markers in melanoma. Histopathology. 2012;60:679-689.
37. Edelbrock MA, Kaliyaperumal S, Williams KJ. Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities. Mutat Res. 2013;743-744:53-66.
38. 6- methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci. 2010;67:3663-3681.
39. 6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta. 2011;1816:179-190.
40. Pegg AE. Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. Chem Res Toxicol. 2011;24:618-639.
41. 6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat Res. 1997;381:227-241.
42. D'Atri S, Tentori L, Lacal PM, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998;54:334-341. (Pubitemid 28368823)
43. 2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 2001;61:1957-1963.
44. 2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol. 2003;23:8306-8315.
45. Caporali S, Falcinelli S, Starace G, et al. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol. 2004;66:478-491. (Pubitemid 39329246)
46. 2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev. 2004;18:1331-1344.